The role of sex steroid hormones in benign prostatic hyperplasia
- 2 January 2017
- journal article
- research article
- Published by Informa UK Limited in The Aging Male
- Vol. 20 (1), 17-22
- https://doi.org/10.1080/13685538.2016.1272101
Abstract
Introduction: The etiology of benign prostatic hyperplasia (BPH) remains a mystery to scientists; estrogen/androgen imbalance in aged men has been implicated. Methods: Thirty (30) apparently healthy men and newly diagnosed BPH patients were recruited from the Ghana Police Hospital. Lower urinary tract syndrome (LUTS) and prostate volume were assessed via the prostate symptom score sheet (IPSS) and abdominopelvic scan, respectively. Laboratory assays for total prostate specific antigen (tPSA) and hormones [androstenedione (AED), testosterone (T), dihydrotestosterone (DHT), androstanedioladiol (3α-adiol), androstanediol (3β-diol), estrone (E1) and estradiol (E2)] were performed via ELISA techniques. Non-parametric analyses were employed. p < 0.05 was considered significant. Results: AED was significantly higher in controls compared to the BPH patients. AKRIC2 (3α-diol/DHT) was significantly higher in the BPH group (p < 0.001) whiles AKRIC1 (3β-diol/DHT) was significantly lower. Estradiol was significantly higher in BPH (p= 0.029). Age correlated negatively with T, while a negative correlation was observed between TIPSS and 3β-diol and AKRIC1. Also, prostate volume correlated negatively with fT.tPSA correlated positively with E2 and aromatase activity (E2/T) and negatively with fT. On multiple linear regression, DHT and 3β-diol remained independent predictors for TIPSS and fT for tPSA. Conclusion: Estrogens and androstanediols seem to play a role in BPH development.Keywords
This publication has 41 references indexed in Scilit:
- Backdoor pathway for dihydrotestosterone biosynthesis: Implications for normal and abnormal human sex developmentDevelopmental Dynamics, 2012
- Androgens and estrogens in benign prostatic hyperplasia: Past, present and futureDifferentiation, 2011
- Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediatedProceedings of the National Academy of Sciences of the United States of America, 2010
- Serum Steroid and Sex Hormone-Binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention TrialAmerican Journal of Epidemiology, 2008
- Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgenJournal of Endocrinology, 2008
- A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoateThe Aging Male, 2007
- Estrogens and aspects of prostate diseaseInternational Journal of Urology, 2006
- Efficacy and tolerability of the dual 5α-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American menProstate Cancer and Prostatic Diseases, 2006
- Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gelThe Aging Male, 2003
- Association of DHEA-S and estradiol serum levels to symptoms of aging menThe Aging Male, 2002